Article

Your Questions Answered About Coronavirus (COVID-19)

Author(s):

LLS

Two hematologist/oncologists on the LLS leadership team, and experts in the field of blood cancer, answer questions and concerns about coronavirus (COVID-19).

The Leukemia and Lymphoma Society recently held a webinar for patients with blood cancers on what they need to know about the COVID-19 pandemic and how it impacts them.

You can view the full webinar here!

Newsletter

Stay up to date on cancer updates, research and education

Subscribe Now!
Related Videos
Image of a woman with brown shoulder-length hair, wearing a khaki colored blazer.
Focusing Research on T-Cell ALL to Further Treatment Options
Image of Dr. Jorge Cortes; a man with short dark hair wearing a suit.
Don’t Delay Bringing Up CML Concerns, a Doctor Says
Image of a man with brown hair.
Most Patients With CML Can Continue Their Normal Lifestyle During Treatment
Image of a woman with short brown hair and glasses.
Organizations Can Help Patients with CML Face the ‘Long Treatment Journey’
Image of a woman with short brown hair and glasses.
Putting Quality of Life into Perspective During CML Treatment
Image of a man with brown hair and a suit and tie.
Understanding the Disease, Treatments Help Patients Navigate a CML Diagnosis
Image of a woman with brown bobbed hair with glasses.
3 Questions to Ask Doctors After a CML Diagnosis
Posttransplant Xospata Does Not Worsen Quality of Life in AML
Posttransplant Xospata Does Not Worsen Quality of Life in AML
Patients with leukemia and lymphoma face racial disparities, financial toxicity, treatment side effects
Patients with leukemia and lymphoma face racial disparities, financial toxicity, treatment side effects
What treatments for leukemia and lymphoma are on the way?
What treatments for leukemia and lymphoma are on the way?
Related Content
Image of FDA sign.
April 8th 2025

FDA Grants Positive Review for AML Drug Trial, First Dosing in 2025

Spencer Feldman
The FDA granted a positive review for an acute myeloid leukemia drug trial, with initial dosing expected in 2025.
cancer horizons logo: a white microphone on a navy blue background
March 11th 2024

Oncology Approvals, Psychological Outcomes for Survivors and an Ovarian Cancer Vaccine

Alex Biese Brielle Benyon
Last week we saw some FDA approvals come through, as well as research that explored the psychosocial outcomes of individuals who survived pediatric rhabdosarcoma.
The first patients have been dosed in a trial of CAR T therapy in relapsed/refractory leukemia or lymphoma: © nobeatsoffierce - stock.adobe.com
March 22nd 2025

First Patients Dosed in WU-CART-007 Trial for Blood Cancer Subtypes

Alex Biese
The first patients have been dosed in a trial of CAR T therapy in relapsed/refractory T cell acute lymphoblastic leukemia or T cell lymphoblastic lymphoma.
Top Headlines on CAR-T Cell Therapy
December 4th 2023

Top Headlines on CAR-T Cell Therapy

Alex Biese Brielle Benyon
From FDA concerns to a potential new drug, CAR-T cell therapies were dominating oncology headlines last week.
It’s easy to think of scientific researchers as existing in a vacuum. © Dr_Microbe - stock.adobe.com.
March 12th 2025

Bringing Together the CAR T-Cell Therapy Community

The Leukemia & Lymphoma Society
It’s easy to think of scientific researchers as existing in a vacuum.
Nutrition is a challenge for many patients with cancer. © - stock.adobe.com
March 12th 2025

Nutrition is Key Following a Cancer Diagnosis

The Leukemia & Lymphoma Society
Nutrition is a challenge for many patients with cancer.